October, 2021 – Extracellular vesicles research in urology and more
In the last months the Laboratory of Experimental Urology published a number of high impact papers on extracellular vesicles in urological research.
In May, we authored the position paper on Urinary Extracellular vesicles by the Urine Task Force of the International Society for Extracellular Vesicles (ISEV). The position paper is authored by more than 40 urologists, nephrologists and biologists specializing in the field. A main emphasis is the importance of rigor and standardization in research as the bridge to clinical translation and is published in the Journal of Extracellular Vesicles (JEV) https://onlinelibrary.wiley.com/doi/10.1002/jev2.12093
This paper was highlighted in a short research letter in European Urology “Urinary Extracellular Vesicles in Urology: Current Successes and Challenges Ahead” (https://www.sciencedirect.com/science/article/abs/pii/S0302283821020558).
Exciting international research collaboration of Dr. Martens-Uzunova and Dr Carolina Soekmadji, Australia resulted in another original research publication on the effect of androgens on the production and cargo of extracellular vesicles published also in JEV https://onlinelibrary.wiley.com/doi/10.1002/jev2.12136
Last but not least, our international collaborative review on “Onco-snoRNA and ribosomal methylation in cancer” was accepted for publication in the special issue on Epitranscriptomics of RNA Biology.
September 20, 2021 – Radiolabeled nanobodies to detect and destroy urothelial carcinoma
The Daniel Den Hoed Foundation, Erasmus MC, awarded a research grant of €500,000 to Prof Guido Jenster (Urology) and Prof Frederik Verburg (Radiology & Nuclear Medicine) for their work on antibodies to specifically detect and treat bladder cancer.
The work on small antibodies against cancer was initiated almost 10 years ago in the Experimental Urology Lab with the selection of nanobodies against PSMA (Prostate Specific Membrane Antigen [PMID: 25977460]) under supervision of Dr. Wytske van Weerden. Nanobodies are small antibodies that can be generated from special antibodies produced by Llamas that have been immunized with human cancer cells. The billions of nanobodies, produced by the Llama can then be used to select those nanobodies that bind a specific protein or a specific cell type such as bladder cancer cells. In close collaboration with the department of Radiology & Nuclear Medicine, the nanobodies can be labeled with a radionuclide for PET/SPECT imaging and irradiation of the tumor for treatment. This work has successfully been performed for the PSMA nanobody and will be expanded using novel nanobodies against bladder cancer.
August 10, 2021 – Tumor testing for advanced bladder cancer to predict treatment efficacy
The Erasmus Mc Bladder Cancer Centre and VitroScan BV join forces on the EVITA project: “Tumor testing for advanced bladder cancer to predict treatment efficacy” The project was awarded with an Erasmus MC-TKI-LSH Match Call (PPP) allowance.
Project coordinators Dr. Joost Boormans, and Dr. Tahlita Zuiverloon: “Together with our affiliated hospitals we have succeeded to establish regional care paths for patients with MIBC and we believe this has substantially improved the quality of care for our patients. However, we are still in desperate need of reliable predictive tests, which could aid in clinical decision making. We are very pleased with the opportunity to leverage our expertise with that of VitroScan within this important study project.”
July 28, 2021 – Towards the development of a catheter decision tool
The functional urology research group was awarded a ZonMw grant to perform a study that will lead to the development of a catheter decision tool. Five percent of the total expenditure on outpatient medical devices in the Netherlands is spent on catheters for clean intermittent catheterization. This puts intermittent catheters in the top four of highest expenditures on outpatient medical devices in the Netherlands. The current study, starting in December 2021, will identify catheter user satisfaction in the Dutch population and determine medical professionals’ view and behavior regarding prescribing clean intermittent catheterization as a last step before the development and validation of a catheter decision tool.